Opus Genetics, Inc. annual report, FY2017

Full document

Business context and reporting period

Filing identity differs from request metadata: the supplied 10-K is for Rexahn Pharmaceuticals, Inc. (ticker RNN), not Opus Genetics, Inc. It reports the fiscal year ended December 31, 2017; the figures below are annual unless stated otherwise, not standalone Q4 results.

Rexahn was a clinical-stage oncology biopharmaceutical company with no approved products or product sales. Its principal programs were RX-3117 and RX-5902, both in Phase 2a development, alongside earlier-stage candidates.

Financial performance and position

  • Revenue: $0 in 2017 and 2016.
  • Expenses and loss: Operating expenses were $17.35 million in 2017, versus $16.41 million in 2016. Net loss was $25.29 million ($0.92 per share), compared with $9.31 million ($0.43 per share). No meaningful gross margin was reported because there was no product revenue.
  • Cash and liquidity: Cash, cash equivalents and marketable securities totaled $26.83 million at year-end, up from $20.32 million. Working capital was $24.90 million, versus $19.04 million. Management said available funds were expected to cover current activities for at least 12 months from issuance of the financial statements.
  • Cash flow: Operating cash use was $15.42 million, versus $13.23 million in 2016. Investing activities used $9.37 million; financing activities provided $22.11 million. Year-end cash and cash equivalents were $8.90 million; the remainder of reported cash and marketable securities was held in marketable securities.
  • Debt and liabilities: The filing reports no conventional borrowings in the supplied financial statements. Total liabilities were $11.52 million, including $7.85 million of warrant liabilities, up from $1.57 million in 2016. Stockholders’ equity was $16.77 million.
  • Research and development: R&D expense was $10.72 million, up 6.2%. RX-3117 accounted for $4.56 million, RX-5902 $2.02 million, and RX-0201 $0.54 million.

Material changes versus prior period

  • Net loss increased by $15.99 million, primarily because a $5.53 million unrealized warrant fair-value gain in 2016 became a $7.59 million unrealized loss in 2017. The warrant remeasurement was noncash and materially affected reported earnings.
  • R&D spending rose as RX-3117 trials advanced; spending on RX-3117 increased from $2.29 million to $4.56 million. RX-0201 spending declined from $1.57 million to $0.54 million.
  • Financing activities included two 2017 registered direct offerings with combined gross proceeds of approximately $18.0 million, plus proceeds from warrant and option exercises. Shares outstanding increased during 2017; the company also effected a one-for-ten reverse stock split in May.
  • 2016 results included a one-time $1.77 million mediation settlement related to a Japanese patent filing; there was no comparable settlement income in 2017.

Outlook, risks, contingencies and unusual items

  • Management expected 2018 RX-3117 and RX-5902 expenses to rise with clinical-trial activity and manufacturing; RX-0201 expenses were expected to fall as the company wound down its internally funded renal-cell-carcinoma program; preclinical spending was expected to remain broadly flat. These are expense expectations, not revenue or earnings guidance.
  • After year-end, the company reported final RX-3117 pancreatic-cancer trial data and updated bladder-cancer data, describing progression-free survival and tumor-shrinkage observations as encouraging. These early-stage findings do not establish efficacy or regulatory approval.
  • In February 2018, Rexahn announced it would stop enrolling patients in its RX-0201 metastatic renal-cell-carcinoma trial in response to changes in the treatment landscape. A separate Haichang collaboration was to fund RX-0201 development in hepatocellular carcinoma in China through a Phase 2a proof-of-concept trial, up to an aggregate $10 million.
  • The company had no product revenue, persistent operating cash burn and expected continued losses; it said further capital would be needed over time and could be unavailable or dilutive. It relied on third parties for clinical research and manufacturing and had no internal commercial sales infrastructure.
  • Other material risks included clinical and regulatory uncertainty, competition, reimbursement and pricing pressures, intellectual-property challenges (including a pending Japanese patent dispute involving RX-5902), and potential delays or cost increases. Estimated remaining costs under R&D vendor agreements were approximately $11.11 million; these agreements were generally terminable on notice. Operating-lease obligations totaled $489,822.
  • The auditor gave unqualified opinions on the financial statements and internal control over financial reporting; management also concluded controls were effective. Warrant liabilities were valued using a model with significant unobservable inputs, making reported earnings sensitive to market movements and estimates.

Important facts for investors to verify

  1. Confirm the issuer: the supplied filing is Rexahn Pharmaceuticals, not Opus Genetics.
  2. Review the complete audited statements and notes for cash runway, warrant terms and potential dilution, and the assumptions driving the $7.85 million warrant liability.
  3. Check subsequent filings for actual trial progress, enrollment, safety and efficacy results, and any changes to the RX-0201 wind-down or Haichang collaboration.
  4. Assess whether financing needs, spending plans and available liquidity have changed since the March 2018 filing date.
  5. Verify the status and potential impact of the RX-5902 Japanese patent litigation and other intellectual-property protections.